Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priya Rao

Showing results (91-100 of 118) with videos related to

Pageof 12
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 25, 2019
Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinomaRoberto Ruiz-Cordero, Priya Rao, Lerong Li, et al.
The American Journal of Surgical Pathology|October 23, 2013
Influence of histologic criteria and confounding factors in staging equivocal cases for microscopic perivesical tissue invasion (pT3a): an interobserver study among genitourinary pathologistsVijayalakshmi Ananthanarayanan, Yi Pan, Maria Tretiakova, et al.
Science Translational Medicine|April 20, 2022
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapyPavlos Msaouel, Sangeeta Goswami, Peter F Thall, et al.
Nature Communications|January 10, 2025
Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trialPavlos Msaouel, Kai Yu, Ying Yuan, et al.
Research Square|November 28, 2024
Safety outcomes and immunological correlates in a prospective clinical trial of immune checkpoint therapy plus debulking surgery for patients with metastatic renal cell carcinomaSangeeta Goswami, Jianjun Gao, Sreyashi Basu, et al.
Journal of the National Cancer Institute|February 17, 2024
Neoadjuvant platinum-based chemotherapy and lymphadenectomy for penile cancer: an international, multi-institutional, real-world studyKyle M Rose, Rachel Pham, Niki M Zacharias, et al.
Nature Communications|February 21, 2025
Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trialSangeeta Goswami, Jianjun Gao, Sreyashi Basu, et al.
Clinical Genitourinary Cancer|October 6, 2018
Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary CarcinomaPavlos Msaouel, Andrew L Hong, Elizabeth A Mullen, et al.
Cancers|December 10, 2021
Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal StudiesDaniel D Shapiro, Melinda Soeung, Luigi Perelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2026
Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary CarcinomaKai Yu, Rebecca S Tidwell, Tharakeswara K Bathala, et al.
Pageof 12

Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 25, 2019
Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinomaRoberto Ruiz-Cordero, Priya Rao, Lerong Li, et al.
The American Journal of Surgical Pathology|October 23, 2013
Influence of histologic criteria and confounding factors in staging equivocal cases for microscopic perivesical tissue invasion (pT3a): an interobserver study among genitourinary pathologistsVijayalakshmi Ananthanarayanan, Yi Pan, Maria Tretiakova, et al.
Science Translational Medicine|April 20, 2022
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapyPavlos Msaouel, Sangeeta Goswami, Peter F Thall, et al.
Nature Communications|January 10, 2025
Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trialPavlos Msaouel, Kai Yu, Ying Yuan, et al.
Research Square|November 28, 2024
Safety outcomes and immunological correlates in a prospective clinical trial of immune checkpoint therapy plus debulking surgery for patients with metastatic renal cell carcinomaSangeeta Goswami, Jianjun Gao, Sreyashi Basu, et al.
Journal of the National Cancer Institute|February 17, 2024
Neoadjuvant platinum-based chemotherapy and lymphadenectomy for penile cancer: an international, multi-institutional, real-world studyKyle M Rose, Rachel Pham, Niki M Zacharias, et al.
Nature Communications|February 21, 2025
Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trialSangeeta Goswami, Jianjun Gao, Sreyashi Basu, et al.
Clinical Genitourinary Cancer|October 6, 2018
Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary CarcinomaPavlos Msaouel, Andrew L Hong, Elizabeth A Mullen, et al.
Cancers|December 10, 2021
Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal StudiesDaniel D Shapiro, Melinda Soeung, Luigi Perelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2026
Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary CarcinomaKai Yu, Rebecca S Tidwell, Tharakeswara K Bathala, et al.
Pageof 12